呼吸道病毒疫苗研发进展。
Progress in respiratory virus vaccine development.
机构信息
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 10001, USA.
出版信息
Semin Respir Crit Care Med. 2011 Aug;32(4):527-40. doi: 10.1055/s-0031-1283289. Epub 2011 Aug 19.
Abstract
Viral respiratory infections cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing respiratory disease, vaccine development has to focus on a limited number of pathogens, such as those that commonly cause serious lower respiratory illness (LRI). Whereas influenza virus vaccines have been available for some time (see the review by Clark and Lynch in this issue), vaccines against other medically important viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIVs), and metapneumovirus (MPVs) are not available. This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development.
摘要
病毒性呼吸道感染可导致婴幼儿以及高危成年人和老年人发生重大发病率和死亡率。尽管许多病毒病原体能够引起呼吸道疾病，但疫苗的开发必须集中在少数病原体上，例如那些常见的严重下呼吸道疾病（LRI）病原体。虽然流感病毒疫苗已经问世一段时间（请参阅本期 Clark 和 Lynch 的综述），但针对其他重要的呼吸道病毒如呼吸道合胞病毒（RSV）、副流感病毒（PIVs）和肺炎支原体（MPVs）的疫苗尚未问世。本综述旨在简要介绍 RSV、PIV 和 MPV 的研究性疫苗的最新情况，这些疫苗已在临床试验中进行了评估或正在临床开发中。
相似文献
1
Progress in respiratory virus vaccine development.呼吸道病毒疫苗研发进展。
Semin Respir Crit Care Med. 2011 Aug;32(4):527-40. doi: 10.1055/s-0031-1283289. Epub 2011 Aug 19.
2
Progress in respiratory virus vaccine development.呼吸道病毒疫苗研发进展
Semin Respir Crit Care Med. 2007 Apr;28(2):243-52. doi: 10.1055/s-2007-976495.
3
Vaccines for the prevention of respiratory viral infections: problems and current status.预防呼吸道病毒感染的疫苗：问题与现状
Expert Opin Investig Drugs. 2004 Jun;13(6):681-9. doi: 10.1517/13543784.13.6.681.
4
Emerging respiratory viruses: challenges and vaccine strategies.新兴呼吸道病毒：挑战与疫苗策略
Clin Microbiol Rev. 2006 Oct;19(4):614-36. doi: 10.1128/CMR.00005-06.
5
Respiratory Viruses of Animals Causing Disease in Humans--Keystone Symposium.导致人类疾病的动物呼吸道病毒——基石研讨会
IDrugs. 2007 Mar;10(3):156-8.
6
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.安卡拉痘苗病毒（MVA）作为抗流感和其他病毒性呼吸道疾病疫苗的生产平台。
Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735.
7
Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines.婴儿对呼吸道病毒感染及减毒活呼吸道病毒候选疫苗的免疫反应。
Vaccine. 1998 Aug-Sep;16(14-15):1423-32. doi: 10.1016/s0264-410x(98)00103-0.
8
VII International Symposium on Respiratory Viral Infections.第七届国际呼吸道病毒感染研讨会
Antivir Ther. 2007;12(4 Pt B):671-93.
9
Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children.预防儿童病毒性呼吸道疾病疫苗的进展
Paediatr Drugs. 2017 Dec;19(6):523-531. doi: 10.1007/s40272-017-0257-x.
10
Nanoparticle vaccines against respiratory viruses.纳米颗粒疫苗对抗呼吸道病毒。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul-Aug;1(4):405-14. doi: 10.1002/wnan.45.
引用本文的文献
1
The structural basis of protective and nonprotective human monoclonal antibodies targeting the parainfluenza virus type 3 hemagglutinin-neuraminidase.靶向3型副流感病毒血凝素-神经氨酸酶的保护性和非保护性人单克隆抗体的结构基础
Nat Commun. 2024 Dec 30;15(1):10825. doi: 10.1038/s41467-024-55101-4.
2
Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.颠覆传统：聚合物纳米颗粒链接疫苗直击呼吸道病毒
Life Sci. 2021 Sep 1;280:119744. doi: 10.1016/j.lfs.2021.119744. Epub 2021 Jun 24.
3
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.呼吸道合胞病毒候选疫苗 3 种制剂在非孕妇女性中的免疫原性和安全性：一项 2 期随机试验。
J Infect Dis. 2019 Oct 22;220(11):1816-1825. doi: 10.1093/infdis/jiz395.
4
The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract.人副流感病毒感染在呼吸道免疫病理学中的作用
Curr Allergy Asthma Rep. 2017 Mar;17(3):16. doi: 10.1007/s11882-017-0685-2.
5
Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract.哺乳动物细胞衍生的呼吸道合胞病毒样颗粒可保护上呼吸道和下呼吸道。
PLoS One. 2015 Jul 14;10(7):e0130755. doi: 10.1371/journal.pone.0130755. eCollection 2015.
6
Recent vaccine development for human metapneumovirus.人偏肺病毒的最新疫苗研发进展
J Gen Virol. 2015 Jul;96(Pt 7):1515-20. doi: 10.1099/vir.0.000083. Epub 2015 Feb 9.
7
Antiviral B cell and T cell immunity in the lungs.肺部的抗病毒B细胞和T细胞免疫。
Nat Immunol. 2015 Jan;16(1):18-26. doi: 10.1038/ni.3056.
8
Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.用于检测抗人呼吸道合胞病毒核蛋白IgG抗体的荧光素酶免疫沉淀系统检测方法的开发。
Clin Vaccine Immunol. 2014 Mar;21(3):383-90. doi: 10.1128/CVI.00594-13. Epub 2014 Jan 8.
9
Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.开发基于寡甘露糖修饰的脂质体鼻用疫苗以预防 3 型人副流感病毒。
Front Microbiol. 2013 Nov 26;4:346. doi: 10.3389/fmicb.2013.00346. eCollection 2013.
10
Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis.呼吸道合胞病毒（RSV）在病毒-宿主界面的调节影响免疫结果和疾病发病机制。
Immune Netw. 2013 Oct;13(5):163-7. doi: 10.4110/in.2013.13.5.163. Epub 2013 Oct 26.
本文引用的文献
1
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.鉴定人副流感病毒 2 型（HPIV-2）V 蛋白的氨基酸残基，这些残基降低了 V 与 MDA5 的结合，并减弱了 HPIV-2 在非人灵长类动物中的复制。
J Virol. 2011 Apr;85(8):4007-19. doi: 10.1128/JVI.02542-10. Epub 2011 Feb 2.
2
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.呼吸道合胞病毒疫苗研发的生物学挑战和技术机遇。
Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x.
3
RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity.RSV 诱导的支气管上皮细胞 PD-L1 表达抑制 CD8+ T 细胞非特异性抗病毒活性。
J Infect Dis. 2011 Jan 1;203(1):85-94. doi: 10.1093/infdis/jiq020.
4
Genetic immunization in the lung induces potent local and systemic immune responses.肺部的基因免疫可诱导强烈的局部和全身免疫应答。
Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22213-8. doi: 10.1073/pnas.1015536108. Epub 2010 Dec 6.
5
The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R.人副流感病毒 1 型的 C 蛋白限制双链 RNA 的积累，否则双链 RNA 会激活 MDA5 和蛋白激酶 R。
J Virol. 2011 Feb;85(4):1495-506. doi: 10.1128/JVI.01297-10. Epub 2010 Dec 1.
6
Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.重组卡介苗诱导呼吸道合胞病毒特异性 Th1 细胞的有效募集促进病毒清除并防止感染。
J Immunol. 2010 Dec 15;185(12):7633-45. doi: 10.4049/jimmunol.0903452. Epub 2010 Nov 17.
7
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).复制缺陷型 5 型腺病毒 HIV 疫苗在 Ad5 血清阴性者中的安全性和免疫原性：一项随机临床试验（HVTN 054）。
PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579.
8
Outcome after bronchiolitis depends on disease definition.细支气管炎的预后取决于疾病的定义。
Thorax. 2011 Mar;66(3):266-7; author reply 267. doi: 10.1136/thx.2010.152488. Epub 2010 Nov 3.
9
Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.含呼吸道合胞病毒 F 和 G 蛋白的新城疫病毒样颗粒的组装和免疫原性。
J Virol. 2011 Jan;85(1):366-77. doi: 10.1128/JVI.01861-10. Epub 2010 Oct 27.
10
Serum antibodies critically affect virus-specific CD4+/CD8+ T cell balance during respiratory syncytial virus infections.血清抗体在呼吸道合胞病毒感染期间严重影响病毒特异性 CD4+/CD8+T 细胞平衡。
J Immunol. 2010 Dec 1;185(11):6489-98. doi: 10.4049/jimmunol.1002645. Epub 2010 Oct 22.
Zotero 插件